ClinicalTrials.gg

Program

nelmastobart

Also written as “Nelmastobart and Docetaxel”, “Nelmastobart in combination with TAS-102 and Bevacizumab” and “hSTC810 400 mg + Paclitaxel”.

Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma, led by STCube.

Furthest: phase 2, since Aug 17, 20235 company-led studies, 3 open or runningNext primary completion: Aug 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
STCube53 open or runningphase 2since Aug 17, 2023Jan 25, 2022Aug 31, 2027phase 2 · NCT07306624

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 25, 2022First study: phase 1 study in Colorectal NeoplasmsFirst studyNCT05231746 · 47 enrolled · United States, Korea, Republic of
  2. Aug 17, 2023Phase 2 study in Extensive Stage Small Cell Lung CancerNCT06016270 · 10 enrolled · United States, South Korea
  3. Feb 17, 2025Phase 2 study in Colorectal NeoplasmsNCT06873763 · 52 planned · South Korea
  4. Dec 14, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07306624 · 62 planned · South Korea
  5. May 27, 2026Phase 1 study in Colonrectal Cancer (CRC)NCT07656038 · 45 planned

Ahead

  1. Aug 31, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07306624
  2. Jul 31, 2028Primary completion: phase 1 study in Colonrectal Cancer (CRC)NCT07656038

TargetBeta

BTN1A1 →read by rule
“A humanized monoclonal antibody directed against the immune checkpoint protein butyrophilin 1A1 (BTN1A1), ”NCIt, by rule

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07656038Colonrectal Cancer (CRC)1Not yet recruitingJul 31, 202845
NCT07306624Carcinoma, Non-Small-Cell Lung · South Korea2RecruitingAug 31, 202762
NCT06873763Colorectal Neoplasms · South Korea2RecruitingDec 202552
NCT06016270Extensive Stage Small Cell Lung Cancer · United States, South Korea2TerminatedJan 23, 202510
NCT05231746Colorectal Neoplasms · United States, Korea, Republic of1CompletedFeb 29, 202447

How it is read

Names in the registry

  • “Nelmastobart and Docetaxel”, 1 entry
  • “Nelmastobart in combination with TAS-102 and Bevacizumab”, 1 entry
  • “hSTC810 400 mg + Paclitaxel”, 1 entry
  • “hSTC810 800 mg + Paclitaxel”, 1 entry
  • “Nelmastobart 800 mg+Trifluridine/Tipiracil+ Bevacizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.